Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1985 4
1986 2
1987 3
1988 1
1989 1
1990 3
1991 2
1992 8
1993 5
1994 6
1995 6
1996 8
1997 3
1998 2
2000 1
2001 2
2002 1
2012 2
2013 2
2016 1
2017 3
2020 3
2021 3
2022 1
2023 3
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Regulation of myelopoiesis.
Bender JG, Van Epps DE, Stewart CC. Bender JG, et al. Comp Immunol Microbiol Infect Dis. 1987;10(2):79-91. doi: 10.1016/0147-9571(87)90001-4. Comp Immunol Microbiol Infect Dis. 1987. PMID: 3304823 Review.
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Mody R, et al. Among authors: bender jg. Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23. Lancet Oncol. 2017. PMID: 28549783 Free PMC article. Clinical Trial.
ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results.
Slotkin EK, Mauguen A, Dela Cruz FS, Ortiz MV, Avutu V, Meyers PA, Wexler LH, O'Donohue TJ, Kinnaman MD, Kelly CM, D'Angelo SP, Keohan ML, Gounder MM, Thornton K, Nacev BA, Chi P, Rosenbaum E, Dickson M, Pachhal S, Somwar R, Ladanyi M, Robb C, Pandit-Taskar N, Hwang S, Price A, Behr G, Reed DR, Kentsis A, Kung AL, Bender JG, Tap WD. Slotkin EK, et al. Among authors: bender jg. JCO Oncol Adv. 2025 Apr 28;2(1):e2400095. doi: 10.1200/OA-24-00095. eCollection 2025. JCO Oncol Adv. 2025. PMID: 40330140 Free PMC article.
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson ADJ, Federico S, Gatz SA, Ortiz M, Lesa G, Scobie N, Gounaris I, Weiner SL, Weigel B, Unger TJ, Stewart E, Smith M, Slotkin EK, Reaman G, Pappo A, Nysom K, Norga K, McDonough J, Marshall LV, Ludwinski D, Ligas F, Karres D, Kool M, Horner TJ, Henssen A, Heenen D, Hawkins DS, Gore L, Bender JG, Galluzzo S, Fox E, de Rojas T, Davies BR, Chakrabarti J, Carmichael J, Bradford D, Blanc P, Bernardi R, Benchetrit S, Akindele K, Vassal G. Pearson ADJ, et al. Among authors: bender jg. Eur J Cancer. 2023 Sep;190:112950. doi: 10.1016/j.ejca.2023.112950. Epub 2023 Jun 21. Eur J Cancer. 2023. PMID: 37441939 Free article. Review.
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD, Allen C, Fangusaro J, Hutter C, Witt O, Weiner S, Reaman G, Russo M, Bandopadhayay P, Ahsan S, Barone A, Barry E, de Rojas T, Fisher M, Fox E, Bender JG, Gore L, Hargrave D, Hawkins D, Kreider B, Langseth AJ, Lesa G, Ligas F, Marotti M, Marshall LV, Nasri K, Norga K, Nysom K, Pappo A, Rossato G, Scobie N, Smith M, Stieglitz E, Weigel B, Weinstein A, Viana R, Karres D, Vassal G. Pearson AD, et al. Among authors: bender jg. Eur J Cancer. 2022 Dec;177:120-142. doi: 10.1016/j.ejca.2022.09.036. Epub 2022 Oct 14. Eur J Cancer. 2022. PMID: 36335782 Free article. Review.
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
Pearson AD, DuBois SG, Buenger V, Kieran M, Stegmaier K, Bandopadhayay P, Bennett K, Bourdeaut F, Brown PA, Chesler L, Clymer J, Fox E, French CA, Germovsek E, Giles FJ, Bender JG, Hattersley MM, Ludwinski D, Luptakova K, Maris J, McDonough J, Nikolova Z, Smith M, Tsiatis AC, Vibhakar R, Weiner S, Yi JS, Zheng F, Vassal G. Pearson AD, et al. Among authors: bender jg. Eur J Cancer. 2021 Mar;146:115-124. doi: 10.1016/j.ejca.2021.01.018. Epub 2021 Feb 16. Eur J Cancer. 2021. PMID: 33601323 Free article. Review.
The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer.
Flores-Toro JA, Jagu S, Armstrong GT, Arons DF, Aune GJ, Chanock SJ, Hawkins DS, Heath A, Helman LJ, Janeway KA, Levine JE, Miller E, Penberthy L, Roberts CWM, Shalley ER, Shern JF, Smith MA, Staudt LM, Volchenboum SL, Zhang J, Zenklusen JC, Lowy DR, Sharpless NE, Guidry Auvil JM, Kerlavage AR, Widemann BC, Reaman GH, Kibbe WA, Doroshow JH; Childhood Cancer Data Initiative Working Groups. Flores-Toro JA, et al. J Clin Oncol. 2023 Aug 20;41(24):4045-4053. doi: 10.1200/JCO.22.02208. Epub 2023 Jun 2. J Clin Oncol. 2023. PMID: 37267580 Free PMC article.
78 results